Related Experiment Video
Updated: Feb 8, 2026

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
Published on: February 18, 2015
Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
Michael J Pishvaian1,2, Robert J Bender2, David Halverson2
1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. pishvaim@georgetown.edu.
Abstract:
Purpose: To broaden access to and implementation of precision medicine in the care of patients with pancreatic cancer, the Know Your Tumor (KYT) program was initiated using a turn-key precision medicine system. Patients undergo commercially available multiomic profiling to determine molecularly rationalized clinical trials and off-label therapies.Experimental Design: Tumor samples were obtained for 640 patients from 287 academic and community practices covering 44 states. College of American Pathologists/Clinical Laboratory Improvement Amendments-accredited laboratories were used for genomic, proteomic, and phosphoprotein-based molecular profiling.Results: Tumor samples were adequate for next-generation sequencing in 96% and IHC in 91% of patients. A tumor board reviewed the results for every patient and found actionable genomic alterations in 50% of patients (with 27% highly actionable) and actionable proteomic alterations (excluding chemopredictive markers) in 5%. Actionable alterations commonly found were in DNA repair genes (BRCA1/2 or ATM mutations, 8.4%) and cell-cycle genes (CCND1/2/3 or CDK4/6 alterations, 8.1%). A subset of samples was assessed for actionable phosphoprotein markers. Among patients with highly actionable biomarkers, those who received matched therapy (n = 17) had a significantly longer median progression-free survival (PFS) than those who received unmatched therapy [n = 18; PFS = 4.1 vs. 1.9 months; HR, 0.47; 95% confidence interval (CI): 0.24-0.94; P adj = 0.03].Conclusions: A comprehensive precision medicine system can be implemented in community and academic settings, with highly actionable findings observed in over 25% of pancreatic cancers. Patients whose tumors have highly actionable alterations and receive matched therapy demonstrated significantly increased PFS. Our findings support further prospective evaluation of precision oncology in pancreatic cancer. Clin Cancer Res; 24(20); 5018-27. ©2018 AACR.
Insights
The Know Your Tumor program successfully implemented precision medicine for pancreatic cancer patients, identifying actionable genomic alterations in 50% of cases. Matched therapies significantly improved progression-free survival, supporting precision oncology
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Pancreatic cancer care lacks broad access to precision medicine.
- The Know Your Tumor (KYT) program aimed to bridge this gap.
- KYT utilized a turn-key system for multiomic profiling.
Purpose of the Study:
- To implement a precision medicine system for pancreatic cancer.
- To identify actionable molecular alterations for targeted therapies.
- To assess the impact of precision medicine on patient outcomes.
Main Methods:
- Collected tumor samples from 640 patients across 287 practices.
- Performed multiomic profiling (genomic, proteomic, phosphoprotein) using accredited labs.
- Utilized a tumor board to review molecular results and recommend treatments.
Main Results:
- Tumor samples were adequate for analysis in over 90% of patients.
- Actionable genomic alterations were found in 50% of patients, with 27% highly actionable.
- Patients receiving matched therapy for highly actionable biomarkers showed significantly longer progression-free survival (4.1 vs. 1.9 months).
Conclusions:
- A comprehensive precision medicine system is feasible in community and academic settings.
- Over 25% of pancreatic cancers harbor highly actionable molecular findings.
- Precision oncology, particularly matched therapy, significantly improves progression-free survival in pancreatic cancer.
Related Concept Videos
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Initiation of Translation
Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
Handwashing II: Pre-procedure and Initial Procedure Steps
The hand washing procedure itself includes the following steps. First, cover cuts, if any, on hands with a waterproof dressing. Cuts and abrasions can become contaminated with bacteria hindering the ability to clean the area thoroughly. In addition, repeated hand washing can worsen an injury. The nails must be short and clean, without nail...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

